Multiple Ascending Dose for Sickle Cell Anemia

"As this is a phase 1 trial, with limited data on its efficacy and safety, Single Ascending Dose receives a rating of 1."

"This clinical trial is accepting twenty individuals between 18 and 55 years of age with anemia or sickle cell. Participants must meet the following stipulations: total bilirubin not exceeding 1.5 times normal, carboxyhemoglobin level via venous blood gas ≤ 3.5%, signed consent form upon enrollment, negative tests for HBsAg, aHCV, aHIV and SARS-CoV-2 prior to medication intake , non smoker/vaper (no use of tobacco or marijuana products within three months before screening), no clinically significant hematological, renal, endocrine pulmonary gastrointestinal cardiovascular hepatic psychiatric"

"The primary metric of this trial is the number of participants that experience treatment-emergent adverse events or serious adverse events. Secondary objectives include measuring time to maximum carboxyhemoglobin concentration, elimination half-life and any laboratory test abnormalities. Blood samples will be taken before and after dosing at various intervals up to 72 hours post administration."

"This medical trial has an age requirement that ranges from 18 to 55 years old."

"Affirmative. Clinicaltrials.gov attests that this research project, initially published on July 25th 2022, is actively engaging participants. The trial calls for 20 individuals to join from a single medical site."

"Affirmative. The clinical trial is actively seeking volunteers, as documented on the clinicaltrials.gov platform; which initially posted the study on July 25th 2022 and provided an update to this information by October 25th of that same year. 20 participants are needed for 1 location."